Paratek Pharmaceuticals

Paratek Pharmaceuticals, based in Boston, Massachusetts, is a biopharmaceutical company focused on developing and commercializing therapies for serious infectious diseases and public health threats. The company’s lead products are NUZYRA, an oral and intravenous broad-spectrum antibiotic used to treat community-acquired bacterial pneumonia and acute bacterial skin infections, and SEYSARA, a tetracycline antibiotic aimed at treating moderate to severe acne vulgaris. Paratek engages in collaborative agreements with various organizations, including Zai Lab and Allergan, and has a licensing agreement with Tufts University to advance treatments for bacterial diseases. Additionally, the company collaborates with the U.S. Army Medical Research Institute to study its antibiotic omadacycline against infectious agents. Founded in 1996, Paratek continues to expand its research, exploring potential treatments for other serious conditions, including multiple sclerosis and systemic inflammatory diseases.